ORPHA:1164
Allergic bronchopulmonary aspergillosis
Also known as: ABPA · Allergic aspergillosis · Hinson-Pepys disease
Publications
6,854
Trials
20
Interventional, condition-specific
Researchers
1,118
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus, clinically manifesting with poorly controlled asthma and recurrent pulmonary infiltrates.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015243
- MeSH:D001229
- OMIM:103920
- UMLS:C3278302
- NCIT:C84547
Additional Mondo synonyms (1)
allergic aspergillosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
6,854 matched papers (3,844 in last 10 years) Source
- Phenotype characterisedPresent
16 HPO annotations (e.g. Abnormal fingernail morphology; Emphysema; Abnormality of the immune system) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
20 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
16
Associated phenotypes · MONDO:0015243
- Abnormal fingernail morphology
- Emphysema
- Abnormality of the immune system
- Hemoptysis
- Abnormal eosinophil morphology
Showing 5 of 16 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
13
Drugs / clinical candidates · MONDO_0015243
- AMPHOTERICIN B·phase 3
- ITRACONAZOLE·phase 3
- PREDNISOLONE·phase 3
- SODIUM CHLORIDE·phase 3
- DUPILUMAB·phase 2
- BENRALIZUMAB·unknown
- BUDESONIDE·phase 2 3
- DEFLAZACORT·phase 2 3
- ERGOCALCIFEROL·phase 2 3
- METHYLPREDNISOLONE·phase 2 3
- OMALIZUMAB·unknown
- PREDNISONE·phase 2 3
- VORICONAZOLE·phase 2 3
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Itraconazole · therapeutic
Literature
Is anyone studying this?
6,854
6,854 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
6,854 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,844 in the last 10 years · low confidence
Phrase hits: 6,854 · MeSH hits: 0
Who's working on it?
1,118
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Agarwal R22 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. agarwal.ritesh@outlook.in.
Papers in Europe PMC - 02Sehgal IS18 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 03Muthu V17 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 04Dhooria S10 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 05Prasad KT9 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 06Aggarwal AN8 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 07
- 08Garg M7 papers · 2026
Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh, 160012, India.
Papers in Europe PMC - 09Rudramurthy SM7 papers · 2026
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 10Li Y6 papers · 2026
Department of Allergy, The First Hospital of Hohhot, Hohhot, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
20
interventional trials for this specific condition
20 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 103 trials are registered for aspergillosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
20 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.8th percentile).
low confidence · 94.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
20 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06174922·RECRUITING·A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
Not reviewed·Conditions: Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT06244979·RECRUITING·iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Not reviewed·Conditions: Pulmonary Aspergillosis · Chronic Pulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT05444946·RECRUITING·Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
Not reviewed·Conditions: Chronic Pulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
Broader category: aspergillosis
103
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05653193·RECRUITING·Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
Not reviewed·Conditions: Chronic Pulmonary Aspergillosis · Aspergillosis·Matched via name phrase
- NCT07337720·NOT YET RECRUITING·Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Not reviewed·Conditions: Aspergillosis Invasive·Matched via name phrase
- NCT07530263·NOT YET RECRUITING·Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Not reviewed·Conditions: Chronic Pulmonary Aspergillosis·Matched via name phrase
- NCT06440915·RECRUITING·Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
Not reviewed·Conditions: Aspergillosis Invasive · Mucormycosis·Matched via name phrase
- NCT03656081·RECRUITING·Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
Not reviewed·Conditions: Chronic Pulmonary Aspergillosis·Matched via name phrase
- NCT06447402·RECRUITING·A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
Not reviewed·Conditions: Chronic Pulmonary Aspergillosis · CPA · Aspergilloma·Matched via name phrase
- NCT03828773·RECRUITING·PTX3-targeted Antifungal Prophylaxis
Not reviewed·Conditions: Candidiasis · Fungal Infection · Acute Myeloid Leukemia · Genetic Predisposition·Matched via name phrase
- NCT06582186·NOT YET RECRUITING·Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
Not reviewed·Conditions: Aspergillosis Invasive · Fungal Infection · Hematologic Malignancy·Matched via name phrase
- NCT03717623·RECRUITING·Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Not reviewed·Conditions: Posaconazole · Pharmacokinetics · Invasive Candidiases · Invasive Aspergillosis·Matched via name phrase
Observational and natural-history studies
17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06645210·NOT YET RECRUITING·Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
Not reviewed·Conditions: Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT07362667·RECRUITING·A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
Not reviewed·Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Airway Clearance·Matched via name phrase
- NCT07530770·RECRUITING·Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
Not reviewed·Conditions: Allergic Bronchopulmonary Aspergillosis · Severe Asthma · ABPA·Matched via name phrase
- NCT07690345·RECRUITING·Fungal Status and Prognosis in ABPA
Not reviewed·Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Colonization·Matched via name phrase
- NCT07362693·RECRUITING·A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
Not reviewed·Conditions: ABPA · Biologics · Allergic Bronchopulmonary Aspergillosis (ABPA) · Cohort Study·Matched via name phrase
- NCT07611838·RECRUITING·Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
Not reviewed·Conditions: Allergic Bronchopulmonary Aspergillosis (ABPA) · Machine Learning · Multi-omics · Multicenter Study·Matched via name phrase
- NCT07493629·RECRUITING·Immune Status and Disease Control of Inflammatory Airway Diseases
Not reviewed·Conditions: Airway Inflammation · Chronic Obstructive Pulmonary Disease (COPD) · Asthma (Diagnosis) · Bronchiectasis·Matched via name phrase
- NCT07040332·RECRUITING·Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Not reviewed·Conditions: Allergic Bronchopulmonary Aspergillosis (ABPA)·Matched via name phrase
- NCT07714863·RECRUITING·ML-Based ABPA Recurrence Prediction and Clinical Utility
Not reviewed·Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Acute Exacerbation·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 19 · after dedupe 19 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 19 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (19)
- isrctn·ISRCTN22936350·Recruiting·A Phase I study evaluating the safety and effects of QX031N in healthy participants, participants with chronic obstructive pulmonary disease and participants with asthma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17596258·Recruiting·AIR-NET- Testing anti-inflammatories for the treatment of bronchiectasis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18210817·No longer recruiting·Measuring response to inhaled asthma therapy using pulmonary imaging
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74240789·No longer recruiting·Understanding the effect of mepolizumab treatment on brain imaging and wellbeing in patients with severe asthma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70034823·No longer recruiting·GREAT-2: a trial of gremubamab compared to placebo in participants with bronchiectasis and chronic Pseudomonas aeruginosa infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15320623·No longer recruiting·A comprehensive disease characterisation study in adult bronchiectasis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17978477·No longer recruiting·A Phase I, double-blind, placebo-controlled, ascending single intravenous dose, safety, tolerability, pharmacokinetic and pharmacodynamic study in healthy participants and non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa administered INFEX702
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15988757·Stopped·A trial looking at the use of bronchodilator and steroid inhalers for preventing flare ups of bronchiectasis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16364688·No longer recruiting·Clinical consequences of Aspergillus disease in cystic fibrosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46346208·No longer recruiting·Laminar airflow in severe asthma for exacerbation reduction
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN85410458·No longer recruiting·Bioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) in cystic fibrosis patients with bronchopulmonary chronic Pseudomonas aeruginosa (PA) infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90016959·No longer recruiting·Omalizumab in non-atopic asthma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93221282·No longer recruiting·Macrolides in refractory asthma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49790596·No longer recruiting·Inhaled Promixin® in the treatment of non-cystic fibrosis bronchiectasis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN64225851·No longer recruiting·Peripheral targeting of inhaled recombinant human deoxyribonuclease in stable cystic fibrosis patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50584238·No longer recruiting·DIEPTE-study: DNase Inhalation in CF Exacerbations, Peripherally Targeted
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61552714·No longer recruiting·Randomised, placebo controlled trial of itraconazole in the treatment of fungal sensitised patients with severe asthma and without allergic bronchopulmonary aspergillosis (ABPA)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14181775·Recruiting·Effects of blocking a messaging protein called TSLP (thymic stromal lymphopoietin) on inflammation in the airways
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17551402·No longer recruiting·AIMSPRO® and the bladder in multiple sclerosis (MS)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Allergic bronchopulmonary aspergillosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Allergic bronchopulmonary aspergillosis" OR "Allergic aspergillosis" OR "Hinson-Pepys disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Allergic bronchopulmonary aspergillosis" OR "Allergic aspergillosis" OR "Hinson-Pepys disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 20 interventional · 17 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"aspergillosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ABPA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (6854) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T16:33:09.707Z
